Recommendation of the President – Vyepti (eptinezumab)

On 26 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 22/2025 on the appraisal Vyepti (eptinezumab) as part of the B.133 drug program “Prophylactic treatment of chronic migraine patients (ICD- 10: G43)”

Publication in Public Information Bulletin (BIP) >>